Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma: A Literature Review and Treatment Perspectives
Advanced hepatocellular carcinoma is a prevalent and potentially aggressive disease. For more than a decade, treatment with sorafenib has been the only approved therapeutic approach. Moreover, no agent has been proven to prolong survival following the progression of disease after sorafenib treatment...
Main Authors: | Daniel M. Girardi, Jana Priscila M. Pacífico, Fernanda P. L. Guedes de Amorim, Gustavo dos Santos Fernandes, Marcela C. Teixeira, Allan A. L. Pereira |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-12-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/14/1/28 |
Similar Items
-
Immunotherapy for hepatocellular carcinomaKey points
by: Alexa Childs, et al.
Published: (2024-10-01) -
The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma
by: Matthew Man Pok Lee, et al.
Published: (2023-09-01) -
Preoperative Immunotherapy in Hepatocellular Carcinoma: Current State of the Art
by: Laschtowitz A, et al.
Published: (2023-02-01) -
Neoadjuvant systemic therapy for hepatocellular carcinoma
by: R. Connor Chick, et al.
Published: (2024-03-01) -
Complications of immunotherapy in advanced hepatocellular carcinoma
by: Young-Gi Song, et al.
Published: (2024-03-01)